Pharma Patents and Medicine Equity in India


  • Moulinath Moitra Student, Department of Law, Amity Law School, Amity University Kolkata, West Bengal, India.
  • Akash Chatterjee Student, Department of Law, Amity Law School, Amity University Kolkata, West Bengal, India.


Pharmacy, Patent, Medicines, Equity, Society, Interests


Pharmacy is a very important sector in Indian Economy and with the bulging population which the country has, its viability attains seemingly greater heights each time. The recent coronavirus pandemic has questioned the entire pharmaceutical regime of the world and disparities between the countries have become even more apparent in dealing with medical emergencies. The role of IPR in this sector stems from the need to on rights to inventing a particular medicine, regulate its sale and reach cross borders with the business arising out of it. Medicines are the lifesaving boons for the human civilisation – ever since days of ancient civilisations, medicines have been prepared to combat mortality and increase lifespan and the quality of life as well. These drugs need to be analysed in terms of relating them with their inventors by way of patents. Considerations of individual interests juxtapose societal and public interests at large, wherein our research proposition finds its place.

How to cite this article: Moitra M, Chatterjee A. Pharma Patents and Medicine Equity in India. Rec Trends Pharm Tech Ind 2022; 4(2): 1-4.


G.S. Srividhya, Introduction to IPR and Patent, Module-2.

Adams plucks Patent & Trademark Attorneys,

G.S. Srividhya, Introduction to IPR and Patent, Module-1.

History of Indian Patent System;

A. Kumar, Legal Service

European Generic Medicines Association, Data Exclusivity

European Generic Medicines Association, Evergreening and Pharma Research Costs,

S. Jayaswal, Extension in Term of Pharmaceutical Patents, Findlaw Australia.

Business Line, Financial Daily from THE HINDU, 2005 October 18.

R. Krishna, Unctad: the financial Express, April 8, 2005.

Patent Act 1970, supra note 3, section 135.

A. Shamsi, Indian Pharmaceutical Industry, Issues and strategies in the Post-GATT/WTO Era, (April 10, 2003).

H. Redwood, New Horizons in India: The consequences of Pharmaceutical Patent Protection (Suffolk, UK: Oldwicks Press, Ltd., 1994).

B. Subramanian, K; Access to medicines and Public Policy Safeguards under TRIPS; Multi stakeholder dialogue on Trade, Intellectual Property and Biological Resources in Asia, Bangladesh, April 19- 20, 2002.

Bergman A, FDI and Spillover Effects in the Indian Pharmaceutical Industry, School of Economics and Management, Lund University, (2006).

G.S. Srividhya, Introduction to IPR and Patent, Module-2.

Volume 3, Issue 2, July – August 2010; Article 008 ISSN 0976 – 044X International Journal of Pharmaceutical Sciences Review and Research Page 43 Available online at PATENT PROTECTION AND INDIAN PHARMACEUTICAL INDUSTRY Damanjeet Ghai.

Vipin Mathur “Patenting of Pharmaceuticals: AnIndian Perspective. Int. J. Drug Dev. & Res., July-September 2012, 4(3): 27-34.